Medgenics' Novel Tissue Implant Approved for Two Hepatitis C Clinical Trials in Israel
Medgenics, Inc. (NYSE: MDGN), the
developer of Biopump™, a novel technology for the sustained production
and delivery of therapeutic proteins in patients using their own tissue,
today announced that Israel's Ministry of Health (MOH) has approved two
Phase I/II clinical trials to assess the safety and efficacy of
INFRADURE™ in patients with hepatitis C. One study will evaluate
previously untreated patients with genotypes 1 and 3, and the other will
study genotype 1 patients who have relapsed after initially responding
to prior treatments.
These are the first approved clinical studies for the use of INFRADURE,
a subcutaneous autologous tissue implant developed to continuously
produce interferon alpha (IFNa).